SCHADENDORF, D.; DUMMER, R.; HAUSCHILD, A.; SANTINAMI, M.; ATKINSON, V.; MANDALA, M.; CHIARION-SILENI, V.; LARKIN, J.; NYAKAS, M.; DUTRIAUX, C.; HAYDON, A.; MORTIER, L.; ROBERT, C.; SCHACHTER, J.; ORTMANN, C.-E.; DE JONG, E.; GASAL, E.; KEFFORD, R.; KIRKWOOD, J. M.; LONG, G. V. Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo. SKIN The Journal of Cutaneous Medicine, v. 3, p. S53, 9 Nov. 2019.